SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Matrix Pharmaceutical (MATX) -- Ignore unavailable to you. Want to Upgrade?

To: Bioscoop who wrote (216)7/27/1999 7:40:00 AM
From: JLIHAI  Read Replies (1) | Respond to of 240
 
No near-term reason to own it. I expect it to remain sleepy for the rest of the year, unless they get another fast-track approval status for another product.

JL



To: Bioscoop who wrote (216)9/12/1999 12:10:00 PM
From: JLIHAI  Read Replies (1) | Respond to of 240
 
MATX will present results of Phase II Intradose Liver Cancer results on November 3 according to their calendar of events.

Volume has been above average lately. Perhaps this indicates things are going well.

JL


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News